-
A Beacon of Hope: UTRX-MYCN-M1 Receives FDA Orphan and Rare Pediatric Designations
A Significant Milestone for Neuroblastoma Research In a promising development for pediatric oncology, UTR Therapeutics Inc. has officially announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Rare Pediatric Disease Designation to its therapeutic candidate, UTRX-MYCN-M1. This candidate is currently being developed for the treatment of neuroblastoma, a rare…
-
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s Camzyos (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
NYSE: $BMY PRINCETON, N.J.–(BUSINESS WIRE) September 30, 2026 — Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos (mavacamten) for the treatment of symptomatic obstructive hypertrophic… Source: Read More
-
Kura Oncology | Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
NASDAQ: $KURA SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (NASDAQ: $KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood cancer research, today announced a clinical collaboration to evaluate Kura’s…
-
Rocket Pharmaceuticals | Unlocking the Potential: RP-L201 and its FDA Designations – A Breakthrough in Pediatric Medicine
NASDAQ: RCKT Rocket Pharmaceuticals has achieved significant milestones with their groundbreaking therapy, RP-L201. The FDA has granted several prestigious designations to RP-L201, including Regenerative Medicine Advanced Therapy (RMAT), Rare Pediatric, Fast Track, and Orphan Drug designations. These designations highlight the immense potential of RP-L201 in treating pediatric patients and emphasize the urgent need for innovative…
-
Aquestive Therapeutics | FDA Acceptance of Libervant™ for Treatment of Seizure Clusters in Young Patients
NASDAQ: AQST The FDA has recently accepted the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film, aiming to tackle the treatment of seizure clusters in children between the ages of two and five. This development provides hope for young patients and their families who have pbeen struggling with the challenges of managing seizure clusters.…